Globenewswire·2025-07-31 05:30Core Insights - The company reported a Q2 sales growth of 10.1% at constant exchange rates (CER) and a business EPS of €1.59, indicating strong performance [1][6] - The sales guidance for 2025 has been refined to high single-digit growth, now at the upper end of the previous range, supported by strong sales performance in the first half of the year [6][8] - Newly launched medicines and vaccines contributed significantly, with a growth rate of 47.3% [6] Sales Performance - Q2 IFRS net sales reported at €9,994 million, reflecting a 6.0% increase, and a 10.1% increase at CER [10] - Dupixent sales increased by 21.1% to €3.8 billion, driven by the launch for COPD [7] - Vaccine sales rose by 10.3% to €1.2 billion, while pharmaceutical launches increased sales by 39.8%, reaching €0.9 billion [7] Financial Metrics - Business EPS was reported at €1.59, up 8.3% at CER and 1.9% reported [7][10] - Free cash flow reached €1,429 million, up 65.8% [10] - IFRS net income reported at €3,939 million, a significant increase of 253.9% [10] Pipeline and Regulatory Progress - The company is advancing its pipeline, with three regulatory approvals and several phase 3 readouts anticipated in the second half of the year [7][9] - Notable regulatory designations include orphan and fast track designations in various therapeutic areas [7] Capital Allocation and Acquisitions - The company closed the acquisition of Blueprint in rare diseases and anticipates closing the Vigil acquisition in neurology [10] - A €5 billion share buyback program is planned for 2025, with 80.3% already repurchased [8]